IP Library Granted Patent US 7,196,071
Granted Patent B2
US 7,196,071 · App. 10/380,354 · Granted Mar 27, 2007

Methods of decreasing or preventing pain using spicamycin derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,196,071
App. No.
10/380,354
Granted
Mar 27, 2007
Kind
B2
Abstract

Methods of providing pain relief by administering a water-soluble derivative of spicamycin. Methods of using pain mediation agents are also provided.

Claims (43)

1. A method of providing pain relief, the method comprising

identifying a subject in need of pain relief; and

administering to the subject an amount of a compound of Formula II, or a salt thereof, effective to provide significant pain relief in the subject,

wherein R 1 and R 2 are different from each other and represent —H or —OH, and R represents (1) an unsubstituted alkyl having one or two carbon atoms, or (2) —H.

2. The method of claim 1 , wherein R has two carbon atoms.

3. A method of providing pain relief, the method comprising

identifying a subject in need of pain relief; and

administering to the subject an amount of a compound of Formula II, or a salt thereof, effective to provide significant pain relief in the subject,

wherein R 1 and R 2 are different from each other and represent —H or —OH, and wherein R is —COCH 2 NH 2 .

4. The method of claim 3 , wherein R 1 is —H and R 2 is —OH.

5. The method of claim 1 , wherein R 1 is —H and R 2 is —OH.

6. The method of claim 1 , wherein the pain is neuropathic pain.

7. The method of claim 6 , wherein the pain is postherpetic neuralgia, phantom or amputation stump pain, diabetic neuropathy, acquired immune deficiency syndrome neuropathy, back pain, visceral pain, or chronic pancreatitic neuropathy.

8. The method of claim 1 , wherein the pain is opioid-resistant.

9. The method of claim 1 , wherein the subject is a mammal.

10. The method of claim 1 , wherein the subject is a human.

11. The method of claim 1 , wherein the compound is administered systemically.

12. The method of claim 1 , wherein the compound is administered at a site of pain in the subject.

13. The method of claim 1 , wherein the compound is administered via an implant.

14. The method of claim 13 , wherein the implant provides slow release of the compound.

15. The method of claim 1 , wherein the compound is administered intravenously.

16. The method of claim 1 , wherein the amount administered is about 1 ng to 4 mg/m 2 body surface area.

17. The method of claim 1 , wherein the amount administered is about 80 ng to 1 mg/m 2 patient body surface area.

18. The method of claim 1 , wherein the amount administered is about 10 to 100 mg/kg body weight.

19. The method of claim 18 , wherein the amount administered is about 100 mg/kg body weight.

20. The method of claim 1 , wherein the compound is administered in an aqueous solution.

21. The method of claim 1 wherein neuropathic pain is selectively relieved over nociceptive pain.

22. The method of claim 3 , wherein the pain is neuropathic pain.

23. The method of claim 22 , wherein the pain is postherpetic neuralgia, phantom or amputation stump pain, diabetic neuropathy, acquired immune deficiency syndrome neuropathy, back pain, visceral pain, or chronic pancreatitic neuropathy.

24. The method of claim 3 , wherein the pain is opioid-resistant.

25. The method of claim 3 , wherein the subject is a mammal.

26. The method of claim 3 , wherein the subject is a human.

27. The method of claim 3 , wherein the compound is administered systemically.

28. The method of claim 3 , wherein the compound is administered at a site of pain in the subject.

29. The method of claim 3 , wherein the compound is administered via an implant.

30. The method of claim 29 , wherein the implant provides slow release of the compound.

31. The method of claim 3 , wherein the compound is administered intravenously.

32. The method of claim 3 , wherein the amount administered is about 1 ng to 4 mg/m 2 body surface area.

33. The method of claim 3 , wherein the amount administered is about 80 ng to 1 mg/m 2 patient body surface area.

34. The method of claim 3 , wherein the amount administered is about 10 to 100 mg/kg body weight.

35. The method of claim 34 , wherein the amount administered is about 100 mg/kg body weight.

36. The method of claim 3 , wherein the compound is administered in an aqueous solution.

37. The method of claim 3 , wherein neuropathic pain is selectively relieved over nociceptive pain.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Nov 5, 2018
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: MIDATECH PHARMA PLC
Reel/Frame 047420/0300 →
SECURITY INTEREST Recorded Jan 2, 2018
From: MIDATECH PHARMA PLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 044970/0892 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2003
From: BORSOOK, DAVID
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 014461/0943 →